19805 N. CREEK PARKWAY, BOTHELL, WA
Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Board Member Dr. Anthony Japour Passes Away
Subjects Dosed in Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
Compensation Committee Approves Stock Options for Directors and Officers
Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload